Pyxis Oncology (PYXS) Non-Current Assets (2020 - 2025)

Pyxis Oncology (PYXS) has 6 years of Non-Current Assets data on file, last reported at $19.4 million in Q4 2025.

• On a quarterly basis, Non-Current Assets fell 21.53% year-over-year to $19.4 million in Q4 2025; TTM through Dec 2025 was $89.2 million, a 46.39% decrease from a year earlier, with the FY2025 full-year figure at $19.4 million, down 21.53% from the prior year.
• Non-Current Assets for Q4 2025 stood at $19.4 million, down from $22.5 million in the prior quarter.
• Over the last five years, Non-Current Assets for PYXS reached as high as $49.1 million in Q4 2023 and fell as low as $1.3 million in Q4 2021.
• Historically, Non-Current Assets has averaged $26.4 million across 5 years, with a median of $24.4 million in 2024.
• Across the five-year window, Non-Current Assets jumped 1743.56% in 2023 and slumped 51.49% in 2025, its largest moves.
• Year by year, Non-Current Assets stood at $1.3 million in 2021, then jumped by 1737.31% to $24.8 million in 2022, then surged by 98.34% to $49.1 million in 2023, then sank by 49.63% to $24.7 million in 2024, then declined by 21.53% to $19.4 million in 2025.
• Per Business Quant data, the three most recent Non-Current Assets figures were $19.4 million in Q4 2025, $22.5 million in Q3 2025, and $23.3 million in Q2 2025.